cytarabine and fosaprepitant

cytarabine has been researched along with fosaprepitant in 3 studies

Research

Studies (3)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	3 (100.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K	1
Clark, SM; Clemmons, AB; DeRemer, DL; Garren, J; Kota, VK; Schaack, L	1
Andrick, B; Clemmons, AB; DeRemer, D; Gandhi, A; Orr, J; Sportes, C	1

Reviews

1 review(s) available for cytarabine and fosaprepitant

Article	Year
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans. Drug discovery today, 2016, Volume: 21, Issue:4 Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk	2016

Trials

1 trial(s) available for cytarabine and fosaprepitant

Article	Year
Randomized, Placebo-Controlled, Phase III Trial of Fosaprepitant, Ondansetron, Dexamethasone (FOND) Versus FOND Plus Olanzapine (FOND-O) for the Prevention of Chemotherapy-Induced Nausea and Vomiting in Patients with Hematologic Malignancies Receiving Hig Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 2018, Volume: 24, Issue:10 Topics: Adult; Aged; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cytarabine; Female; Hematologic Neoplasms; Hematopoietic Stem Cell Transplantation; Humans; Induction Chemotherapy; Male; Melphalan; Middle Aged; Morpholines; Nausea; Olanzapine; Ondansetron; Podophyllotoxin; Vomiting	2018

Article

Year

Randomized, Placebo-Controlled, Phase III Trial of Fosaprepitant, Ondansetron, Dexamethasone (FOND) Versus FOND Plus Olanzapine (FOND-O) for the Prevention of Chemotherapy-Induced Nausea and Vomiting in Patients with Hematologic Malignancies Receiving Hig

Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 2018, Volume: 24, Issue:10

Topics: Adult; Aged; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cytarabine; Female; Hematologic Neoplasms; Hematopoietic Stem Cell Transplantation; Humans; Induction Chemotherapy; Male; Melphalan; Middle Aged; Morpholines; Nausea; Olanzapine; Ondansetron; Podophyllotoxin; Vomiting

2018

Other Studies

1 other study(ies) available for cytarabine and fosaprepitant

Article	Year
Fosaprepitant for the prevention of nausea and vomiting in patients receiving BEAM or high-dose melphalan before autologous hematopoietic stem cell transplant. Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners, 2016, Volume: 22, Issue:3 Topics: Aged; Antiemetics; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cohort Studies; Cytarabine; Female; Hematopoietic Stem Cell Transplantation; Humans; Male; Melphalan; Middle Aged; Morpholines; Nausea; Podophyllotoxin; Prospective Studies; Retrospective Studies; Transplantation Conditioning; Vomiting	2016

Article

Year

Fosaprepitant for the prevention of nausea and vomiting in patients receiving BEAM or high-dose melphalan before autologous hematopoietic stem cell transplant.

Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners, 2016, Volume: 22, Issue:3

Topics: Aged; Antiemetics; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cohort Studies; Cytarabine; Female; Hematopoietic Stem Cell Transplantation; Humans; Male; Melphalan; Middle Aged; Morpholines; Nausea; Podophyllotoxin; Prospective Studies; Retrospective Studies; Transplantation Conditioning; Vomiting

2016